Biological Markers for Post-Traumatic Stress Disorder

NCT ID: NCT05213858

Last Updated: 2024-02-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

300 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-01-01

Study Completion Date

2026-01-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The current study aims to evaluate the sensitivity and specificity of a combination of various objective biomarkers for the diagnosis of PTSD.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PTSD affects a major fraction of military combatants and is also very common in the general population. Like other psychiatric conditions, the diagnosis of PTSD is currently based on an interview and questionnaires. However, the validity of these tools is limited since it depends on the evaluator's skills, and on patient compliance and mental status; and may be prone to exaggeration or minimization of symptoms. This prompts an urgent need for evaluation that will combine biomarkers for objective diagnosis, and follow up of individuals with PTSD.

Knowledge has grown in recent years regarding the biologic pathophysiological cascade responsible for the development of a "non-healing wound in the brain" that characterizes PTSD. Shortly after the traumatic experience, fundamental changes in autonomic nervous and endocrine activity are evident, together with changes in brain function; these can become chronic in those with long-standing unremitting PTSD. Several studies indicate good correlations of the diagnosis and severity of PTSD, with objective biological measures such as heart rate variability (HRV), brain connectivity and endocrine activity. However, the currently available data on these biological variables are still not sufficient to be used for diagnosis of PTSD.

The aim of the current study is to characterize the biological fingerprint of PTSD, by using a combination of biological measures, for an objective diagnosis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Post Traumatic Stress Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CAPS questionnaire

PTSD diagnosis and severity will be done using the CAPS-5 questionnaire.

Intervention Type DIAGNOSTIC_TEST

Beck Depression Inventory

depression symptoms will be measured by the BDI-II. The BDI-II consists of 21 items and uses a 0 to 3 severity scale. Total scores range from 0 to 63, with higher scores indicating more severe depression.

Intervention Type DIAGNOSTIC_TEST

The Fibromyalgia Impact Questionnaire

The FIQ was developed from information gathered from patient reports, functional status instruments and clinical observations. This instrument measures physical functioning, work status (missed days of work and job difficulty), depression, anxiety, morning tiredness, pain, stiffness, fatigue and well-being over the past week.

Intervention Type DIAGNOSTIC_TEST

The Pittsburgh Sleep Quality Index

sleep patterns will be measured using the PSQI. This index assesses the quality and patterns of sleep in adults. It differentiates "poor" from "good" sleep quality by measuring seven components: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, the use of sleeping medications and daytime dysfunction over the last month. Items are rated using a 0 to 3 scale. The component scores are summed to produce a global score (range 0 to 21). Higher scores indicate worse sleep quality.

Intervention Type DIAGNOSTIC_TEST

Depression, Anxiety and Stress Scale-21 items

The DASS-21 is a three-scale self-report questionnaire designed to measure the emotional state of depression, anxiety and stress. Each scale contains 7 items, divided into subscales with similar content. Scores range between 0 and 21 in each subcategory.

Intervention Type DIAGNOSTIC_TEST

Traumatic Events Questionnaire

The TEQ examines experiences of traumatic events (e.g. sexual abuse, accidents and crime) that are considered potential triggers of PTSD symptoms. To assess trauma intensity, respondents provide information for each event that was experienced, as well as their age at the time of the event. The items are measured on a 9-point Likert scale from "not at all" to "severely/extremely". The TEQ has previously been used in Israel.

Intervention Type DIAGNOSTIC_TEST

Clinician Administered Dissociative States Scale

The CADSS is a 28-item structured clinical interview to assess state dissociation.

Intervention Type DIAGNOSTIC_TEST

A diary will be used for seven consecutive nights

A diary will be used for seven consecutive nights for the evaluation of:

* Mean sleep latency
* The number and duration of awakenings.
* Subjective total sleep time
* Subjective wake after sleep onset
* Sleep efficiency

Intervention Type DIAGNOSTIC_TEST

MRI

Brain imaging will include DTI and resting state for structural and functional MRI scanning. Images will be acquired on MAGNETOM Vida 3T Scanner, configured with 64-channel receiver head coils (Siemens Healthcare, Erlangen, Germany) at the Department of Radiology at Shamir Medical Center.

Intervention Type DIAGNOSTIC_TEST

Functional brain imaging

Functional magnetic resonance imaging (fMRI) is widely used to study the operational organization of the human brain. This technology measures brain activity by detecting changes associated with blood oxygenation, using blood-oxygen-level-dependent imaging (BOLD) contrast.

Intervention Type DIAGNOSTIC_TEST

EEG analysis

EEG will be obtained using a point-of care device that consists of an EEG-Sense Headset, EEG-Sense Single-Use brush sensors, a pneumatic sensor positioning mechanism, EEG sampling electronics and software. The EEG-Sense Headset is an EEG electrode positioning system that quickly places electrodes in a uniform and consistent manner, to transfer electrophysiological EEG signals from an individual to a suitable EEG data collection device. The device is nonsterile, non-invasive and non-radiation emitting, and was developed for use in healthcare facilities and hospitals. Typical set-up and procedure time is several minutes. The device does not contain biologics, drugs, coatings or any claim of sterility. The EEG-Sense Single-Use brush sensors are made from well-established medical-grade materials; the Headset is made from Nylon 101. Electronic components and harnesses are embedded between two layers of nylon and are attached to each electrode port.

Intervention Type DIAGNOSTIC_TEST

Autonomic nervous system monitors

Data will be collected using Empatica's E4 wristband. Each of the study participants will wear the wristband for 7 days.

Data collected from the band will include:

ACC - Data from 3-axis accelerometer sensor in the range \[-2g, 2g\]. (sampled at 32 Hz) BVP - Data from photoplethysmography (PPG). (sampled at 64 Hz) EDA - Data from the electrodermal activity sensor in μS. (sampled at 4 Hz) IBI - Inter-beat intervals. (intermittent output with 1/64 second resolution) TEMP - Data from temperature sensors, expressed in degrees on the Celsius (°C) scale. (sampled at 4 Hz)

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. The willingness and ability to read, understand and sign an informed consent form.
2. Age 20-60 years.
3. A history of more than 2 years of combat service, and of at least one potentially life-threatening combat experience.
4. One year or more after the last combat experience.

Exclusion Criteria

1. Inability to attend scheduled clinic visits or comply with the study protocol
2. A history of traumatic brain injury or any other known brain pathology.
3. Substance use, except for prescribed cannabis, if it can be withheld for at least 24 hours prior to the study evaluation.
4. A current psychiatric disorder other than PTSD.
5. The inability to perform an awake brain MRI.
Minimum Eligible Age

20 Years

Maximum Eligible Age

60 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assaf-Harofeh Medical Center

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

keren doenyas-barak, md

Role: PRINCIPAL_INVESTIGATOR

sagol center for hyperbaric medicine

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Assaf-Harofeh Medical Center

Ramla, , Israel

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Israel

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

keren doenyas-barak, MD

Role: CONTACT

+972544215487

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Shai Efrati, MD

Role: primary

97289779395

keren doenyas-barak, MD

Role: backup

97289779395

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

178-21

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

CPT-fMRI Study for PTSD
NCT03229915 COMPLETED NA
Imaging the Neuroimmune System in PTSD
NCT04236986 COMPLETED PHASE1